Cosopt Versus Xalatan

Pharmaceutical Research Network

Status and phase: Completed; Phase 4

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Treatments: Drug: dorzolamide/timolol maleate fixed combination; Drug: timolol maleate 0.5%; Drug: latanoprost 0.005%; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00273429

PRN 04-015

Details and patient eligibility

About

To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
• intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
• ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion criteria

• any contraindications to study medications
• any anticipated change in systemic hypertensive therapy during the trial

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind